Agilent Technologies is acquiring Proscia, an AI-powered digital pathology software provider, for up to $270 million. This strategic move aims to expand Agilent's presence in AI-enabled diagnostics, strengthen its digital pathology capabilities, and enhance its long-term growth profile through recurring software revenue.
Agilent Technologies is acquiring Proscia, a digital pathology software provider, for $240 million cash at closing plus $30 million in performance milestones. This acquisition is significant as it directly expands Agilent's capabilities in the rapidly growing field of AI-powered diagnostics and digital pathology, building on an existing partnership. It allows Agilent to offer more integrated laboratory workflows and strengthens its higher-margin, recurring-revenue software business, which is positive for long-term growth. The deal is expected to close in early fiscal 2027, and Agilent's stock saw a positive premarket reaction, indicating investor approval of this strategic move.